IL-18对胶质瘤大鼠外周血TGF-β、CD8^+T水平的影响  

The effects of IL-18 on the level of TGF-β,CD8^+T in the peripheral blood of glioma rat

作　　者：宋杨英[1] 程天军[2] 黄淑珍[3] 李振东[1] 单保恩[4] 杨宝友 白波[1] 

机构地区：[1]玉田县医院检验科,河北唐山064100 [2]玉田县医院肿瘤外科,河北唐山064100 [3]玉田县医院高压氧,河北唐山064100 [4]河北医科大学第四医院科研中心,河北石家庄050011

出　　处：《现代肿瘤医学》2014年第12期2818-2820,共3页Journal of Modern Oncology

摘　　要：目的:分析IL-18对胶质瘤大鼠外周血中TGF-β水平及CD8+T比例的影响。方法:将大鼠随机分为3组,每组5只。分别用立体定向技术接种9L/IL-18、9L、9L/LXSN细胞,建立实验动物模型。14天后,取各组大鼠外周血,ELISA法检测各组大鼠外周血中TGF-β细胞水平。流式细胞术检测各组大鼠外周血中CD8+T比例。结果:接种9L/IL-18组大鼠外周血中TGF-β的水平为(111.5±5.9)ng/L,显著低于接种9 L、9 L/LXSN细胞组[(133.4±3.7)ng/L、(127.9±4.0)ng/L](P<0.05)。前者外周血中CD8+T比例(32.3±2.2)%与后两组相比[(分别为(22.3±0.8)%、(22.0±0.7)%]显著增高,差异有统计学意义(P<0.05)。结论:IL-18可降低荷瘤鼠外周血中TGF-β水平,提高CD8+T细胞比例,从而改善荷瘤鼠免疫抑制状态,提高免疫功能。Objective： To analyze the effects of IL- 18 on the level of TGF- β and the percentage of CD8^＋T in the peripheral blood of glioma rat. Methods： The rats were divided into three groups,five in each group,randomly. The cells of 9L / IL- 18,9L,9L / LXSN were inoculate into the brain of rat in each group. To establish the animal models by the stereotactic technique. After two weeks,collect the peripheral blood of each group,the level of TGF- β in the peripheral blood of rats was measured by ELIAS. The percentage of CD8^＋T lymphocytes was analyzed with FACS. Results： The level of TGF- β in the peripheral blood of rats inoculated with 9 L / IL- 1 8 cells [（ 111. 5 ± 5. 9） ng /L]was weakend to that implanted with 9 L and 9 L / LXSN cells [（ 133. 4 ± 3. 7） ng / L,（ 127. 9 ± 4. 0） ng / L]（ P 0. 05）,compared with the other two groups [（ 22. 3 ± 0. 8） %,（ 22. 0 ± 0. 7） %] the percentage of CD8＋T lymphocytes in the peripheral blood of rats inoculated with 9L / IL- 18 cells [（ 32. 3 ± 2. 2） %] was significantly increased（ P 0. 05）. Conclusion： IL- 18 could decrease the level of TGF- β and enhance the percentage of CD8^＋T cells in the peripheral blood of glioma rats to improve the state of immunosupperssion and enhance the immunitive function.

关 键 词：IL-18 胶质瘤 TGF-Β CD8^+T 

分 类 号：R730.264[医药卫生—肿瘤]